Key result
Age over 60 years (OR 4.80; 95% CI 2.16-10.68), capecitabine dose >3000 mg/day, and receiving ≥5 cycles were independent predictive factors for the development of grade 2 and 3 hand-foot syndrome.
Why the study?
Capecitabine-induced hand-foot syndrome significantly impairs quality of life, but its underlying mechanisms are not clearly understood, making the identification of predictive factors critical.
What are the predictive factors for the development of grade 2 and grade 3 hand-foot syndrome in patients treated with capecitabine?
Cohort (n=205)
What are the predictive factors for the development of grade 2 and grade 3 hand-foot syndrome in patients treated with capecitabine?
Answers are grounded in this paper and cite their sources.
Age >60, capecitabine dose >3000 mg/day, and ≥5 planned cycles are significant predictors of grade 2/3 hand-foot syndrome, which can guide clinical monitoring.
Background: Capecitabine-induced hand-foot syndrome (HFS) is a common condition that significantly affects patients’ quality of life. The exact underlying mechanisms are currently not clearly understood. Therefore, the study of predictive factors for HFS is of critical importance. Materials and methods: This prognostic factor research used a retrospective observational cohort as the study design. Data collected from the medical records of 205 patients treated with capecitabine between January 2019 and June 2022 were subjected to univariable and multivariable regression analysis to determine the predictive factors for the development of grade 2 and grade 3 HFS. Results: The incidence of grade 2 and grade 3 HFS was 26.8%. The independent predictive factors, such as age over 60 years (OR 4.80, 95% CI: 2.16–10.68, P <0.001), capecitabine dose greater than 3000 mg/day (OR 2.47, 95% CI: 1.09–5.59, P =0.030), and the number of cycles five or more in the total capecitabine regimen (OR 2.94, 95% CI: 1.29–6.71, P =0.01), were significantly associated with the development of grade 2 and grade 3 HFS. Conclusions: Independent predictive factors for the development of grade 2 and grade 3 HFS in patients treated with capecitabine include age over 60, capecitabine dose greater than 3000 mg/day, and patients who plan to undergo five or more cycles in the total capecitabine regimen. This knowledge can be valuable for guiding clinical monitoring and follow-up of patients.
No takes yet. Share an insight, caveat, or question.
Chantharakhit et al. (2023) conducted a cohort in Capecitabine-induced hand-foot syndrome (n=205). Age >60 years, capecitabine dose >3000 mg/day, and ≥5 cycles was evaluated on Development of grade 2 and grade 3 HFS (OR 4.80, 95% CI 2.16-10.68, p=<0.001). Age over 60 years (OR 4.80; 95% CI 2.16-10.68), capecitabine dose >3000 mg/day, and receiving ≥5 cycles were independent predictive factors for the development of grade 2 and 3 hand-foot syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: